Maridea Wealth Management LLC Buys Shares of 6,615 Harrow, Inc. (NASDAQ:HROW)

Maridea Wealth Management LLC purchased a new position in Harrow, Inc. (NASDAQ:HROW) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 6,615 shares of the company’s stock, valued at approximately $222,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Harrow by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company’s stock worth $62,809,000 after purchasing an additional 5,225 shares in the last quarter. State Street Corp raised its stake in shares of Harrow by 2.2% in the 3rd quarter. State Street Corp now owns 730,973 shares of the company’s stock worth $32,865,000 after buying an additional 15,554 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Harrow by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 722,730 shares of the company’s stock worth $32,500,000 after buying an additional 3,960 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Harrow by 1.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 255,218 shares of the company’s stock valued at $8,563,000 after buying an additional 3,589 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Harrow by 443.1% during the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock valued at $10,717,000 after buying an additional 194,480 shares in the last quarter. 72.76% of the stock is currently owned by institutional investors.

Harrow Trading Down 6.0 %

Shares of NASDAQ HROW opened at $26.21 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a 12 month low of $9.86 and a 12 month high of $59.23. The company has a market cap of $933.47 million, a price-to-earnings ratio of -27.88 and a beta of 0.69. The business has a fifty day simple moving average of $28.90 and a 200-day simple moving average of $37.99.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Thursday, March 27th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The company had revenue of $66.83 million during the quarter, compared to analyst estimates of $66.01 million. Sell-side analysts predict that Harrow, Inc. will post -0.53 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on HROW. HC Wainwright reiterated a “buy” rating and issued a $57.00 price target on shares of Harrow in a research report on Tuesday, March 18th. B. Riley dropped their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a report on Wednesday, December 4th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.